Last Updated: 10/12/2025
Evaluation of the implementation and effectiveness of intermittent preventive treatment for malaria using dihydroartemisinin-piperaquine on reducing malaria burden in school aged children in Tanzania (IPTsc)
Objectives
Primary objective: To evaluate the implementation of IPTsc using DP and its effectiveness on reducing the burden of malaria in school children living in high endemic areas.
Secondary objectives are to:
- Assess the feasibility and acceptability of IPTsc using DP in school children
- Determine the proportion of school children using bed nets
- Determine proportion of school children who received IPTsc among all targeted school children.
- Determine impact of IPTsc on clinical malaria incidence in school children.
- Determine impact of IPTsc on haemoglobin concentration and
- Assess the cardio-safety of DP on school children
Exploratory objectives:
- Determine the impact of IPTsc with DP on drug resistance (DP polymorphism).
- Determine impact of IPTsc on school attendance.
- Determine malnutrition level in school children.
In Tanzania, according to the National Malaria Control Programme (NMCP), malaria prevalence has declined from an average of 18.1% in 2008 to 7% in 2017, marked as an epidemiological transition from meso-endemic to hypo-endemic levels with variation across and within regions and/or councils. Children of school-age have become increasingly more vulnerable as compared to those aged less than five years. In high-transmission settings, up to 70% of school-aged children harbour malaria parasites which is mostly asymptomatic, accounting for around 50% of the mortality, 13-50% of all school absenteeism. The NMCP developed a supplementary malaria midterm strategic plan (SMMSP 2018-2020) to customise malaria interventions by stratifying the burden of malaria in Tanzania mainland and recommended use of Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment in school children (IPTsc) in high malaria strata. The investigators plan to evaluate the implementation of IPTsc using DP, given three times a year, for evidence on the operational feasibility and effectiveness of IPTsc on clinical malaria incidence at a high endemic area in Handeni District Council (DC), Handeni Town Council (TC) and Kilindi DC of Tanga region, Tanzania.
The study is an effectiveness-implementation hybrid trial to assess feasibility and effectiveness of IPTsc using DP against standard of care (control). Wards in the three study districts (Handeni DC, Handeni TC and Kilindi DC) will be the randomisation unit (clusters). Each ward will be randomised to implement IPTsc or not (control). In all wards in the IPTsc arm, the interventional drugs (DP) will be given at an interval of four months, three times a year. For study evaluation of the impact of intervention, in each district representative randomly selected wards, will provide randomly selected school per ward (24 in total) to formulate part of evaluable children per intervention. Mixed design methods will be used to assess the feasibility and acceptability of implementing IPTsc as part of a more comprehensive school children health package.
The study is expected to be operationally feasible given existing school health programme for Neglected Tropical Disease (NTD) control and the school net programme (SNP). IPTsc is expected to increase malaria case management effectiveness and to have additional effect in reducing the burden of disease on top of optimal access to malaria case management (MCM) and malaria vector control (MVC) initiatives e.g. early diagnosis and treatment, and insecticide-treated nets (ITNs) coverage, respectively.
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Interventional Model Description: The study is an effectiveness-implementation hybrid trial to assess feasibility and effectiveness of IPTsc using DP against standard of care (control). Wards in the three study districts (Handeni DC, Handeni TC and Kilindi DC) will be the randomisation unit (clusters). Each ward will be randomised to implement IPTsc or not (control).
- Masking: None (Open Label)
- Primary Purpose: Prevention
- Clinical trial registration: NCT04245033
Drug Resistance
Drug-based Strategies
Impact of Interventions
Monitoring & Evaluation
Vulnerable Populations
Jan 2019 — Dec 2020
$491,191


